News

The stock has been in fine form on the market in the past year despite volatility.

The payment card services provider is still an evergreen investment.

“These whips are the market process. This is the market zigging in order to zag.” Universa Investments' Mark Spitznagel told Fortune.

While inflation has eased to 2.9% in July, interest rates remain elevated, with the Federal Reserve’s key rate currently at 5.25% to 5.50%. However, it is widely expected that the Fed will begin cutting rates as early as next month. A reduction in rates is likely to send ripples across various sectors, with the biotech industry being particularly affected. Biotech companies, which often operate with significant overhead costs, are especially sensitive to changes in interest rates. But with a rat

Investors can find compelling opportunities in beaten-down stocks.

Rivian's next EV will drive the stock -- the question is in which direction.